SCHEMBL681618

SCHEMBL681618

CCCCN(CCCC)CCNC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.48
PRMT3 O60678 1/20 0.43
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT1 Q99873 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
KDM5A P29375 4/20 0.37
PHF8 Q9UPP1 2/20 0.35
KDM4C Q9H3R0 2/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA9 Q16790 2/20 0.34
TSHR P16473 2/20 0.33
ALDH1A1 P00352 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24065809 1.00 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL20118741 0.95 EPHX1 (0.44) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL19575770 0.90 EPHX1 (0.44) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL12478475 0.90 EPHX1 (0.44) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL681370 0.90 EPHX1 (0.55) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL27427924 0.89 EPHX1 (0.39) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL20283561 0.89 EPHX1 (0.39) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL23223465 0.89 EPHX1 (0.39) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL12559633 0.89 EPHX1 (0.39) EPHX1PRMT3CARM1PRMT6PRMT1
SCHEMBL18732127 0.88 EPHX1 (0.48) EPHX1PRMT3CARM1PRMT6PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634265-A1 POLYESTERS CLARIANT INTERNATIONAL LTD (CH) 2025-10-22 EP disclosed
WO-2024126303-A1 POLYESTERS CLARIANT INTERNATIONAL LTD (CH) 2024-06-20 WO disclosed
WO-2023006062-A1 NUCLEIC ACID VACCINES FOR MUTANT CORONAVIRUS Suzhou Abogen Biosciences Co., Ltd. (CN) 2023-02-02 WO disclosed
US-20220356351-A1 HYDROPHOBICALLY MODIFIED ALKYLENE OXIDE POLYMER MIXTURE ROHM AND HAAS COMPANY 2022-11-10 US disclosed
WO-2022002040-A1 LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS Suzhou Abogen Biosciences Co., Ltd. (CN) 2022-01-06 WO disclosed
WO-2021096689-A1 HYDROPHOBICALLY MODIFIED ALKYLENE OXIDE POLYMER MIXTURE ROHM AND HAAS COMPANY (US) 2021-05-20 WO disclosed
US-20210017380-A1 BIOCIDE FREE ASSOCIATIVE THICKENER ROHM AND HAAS COMPANY 2021-01-21 US disclosed
EP-3766346-A1 BIOCIDE FREE ASSOCIATIVE THICKENER Rohm and Haas Company (US) 2021-01-20 EP disclosed
US-10723837-B2 Method of preparing poly(alkylene carbonate) via copolymerization of carbon dioxide/epoxide in the presence of novel complex SK INNOVATION CO., LTD. (KR) 2020-07-28 US disclosed
EP-2976348-B1 METHOD OF PREPARING POLY(ALKYLENE CARBONATE) VIA COPOLYMERIZATION OF CARBON DIOXIDE/EPOXIDE IN THE PRESENCE OF NOVEL COMPLEX SK INNOVATION CO LTD (KR) 2019-11-20 EP disclosed
WO-2009099582-A2 COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE DIAKINE THERAPEUTICS, INC. (US) 2009-08-13 WO disclosed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US disclosed
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2008-12-04 US disclosed
US-7393827-B2 Pharmaceutical compositions and methods for restoring β-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2008-07-01 US disclosed
US-7393827-B2 Pharmaceutical compositions and methods for restoring β-cell mass and function DIAKINE THERAPEUTICS, INC. (US) 2008-07-01 US disclosed
WO-2008011518-A2 ENCAPSULATION SYSTEM DIAKINE THERAPEUTICS, INC. (US) 2008-01-24 WO disclosed
WO-2007146786-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING B-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2007-12-21 WO disclosed
WO-2006074051-A2 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION DIAKINE THERAPEUTICS, INC. (US) 2006-07-13 WO disclosed
US-4676803-A Reactive azo dyestuffs, free from anionic groups and containing a basic group and halogenotriazinyl radical and useful for dyeing cellulose/polyester BAYER AKTIENGESELLSCHAFT (DE) 1987-06-30 US disclosed
US-4503224-A FIBER-REACTIVE, COTTON-POLYESTER BLENDS BAYER AKTIENGESELLSCHAFT (DE) 1985-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10723837-B2 Method of preparing poly(alkylene carbonate) via copolymerization of carbon dioxide/epoxide in the presence of novel complex SMARCC2, SMARCC1, CLNS1A EPHX1 1159/4885PRMT3 4222/4885CARM1 1779/4885
US-20080300189-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION IAPP, PNLIP, AMY2A EPHX1 1435/4885PRMT3 3363/4885CARM1 3045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.